<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02866149</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2015-02</org_study_id>
    <nct_id>NCT02866149</nct_id>
  </id_info>
  <brief_title>Analysis of Circulating Tumor Markers in the Blood (ALCINA)</brief_title>
  <acronym>ALCINA</acronym>
  <official_title>Analysis of Circulating Tumor Markers in the Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory study on blood-borne biological markers and their correlation with clinical and
      pathological characteristics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exploratory multi-cohort study including different types of cancer (different organs and/or
      different histological types).

      Each kind of blood-borne biological markers analyses corresponds to a cohort.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of the analysis of different blood-borne tumor biomarkers</measure>
    <time_frame>3 years</time_frame>
    <description>Success rate of the tested detection techniques. The success rate of a given detection technique is calculated by the ratio &quot; detection success &quot; / &quot; number of screened patients &quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation with biological and clinical data</measure>
    <time_frame>3 years</time_frame>
    <description>Number of biological analysis results correlated to clinical data. Establishment of a proof of concept</description>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">760</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - &quot;Anti checkpoint&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Monitoring of patients with tumours treated by immune therapy.
Timing of blood sampling:
inclusion
after #8 weeks on therapy
at progression or 6 months from inclusion for patient without progressive disease
if toxicity grade 3 or 4, or grade 2 until 1 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - &quot;Oncoscan®&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Monitoring of patients with HER 2+/- breast cancer and correlation with genome-wide copy number, loss of heterozygosity detection, as well as identification of frequently tested somatic mutations (Oncoscan® assays).
Timing of blood sampling:
inclusion
after 1 cycle of therapy (weeks 3-4)
up to 2 other samples, timepoints decided by the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - &quot;CirCe-PLA&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Feasibility of Proximity-Ligation Assay (PLA) to study membrane proteins dimerisation by on isolated tumour cells in patients with HER2+/- breast cancer (HER 2+/-).
One tumor sampling.
Timing of blood sampling:
Inclusion
up to 3 other samples, timepoints decided by the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - &quot;CDX PDX&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Establishment of xenografts from tumor (PDX) and from Circulating Tumour Cell (CDX) by tumour and blood sampling.
One tumor sampling.
Timing of blood sampling:
Inclusion
up to 3 other samples, timepoints decided by the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 - &quot;Post-TP53&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Follow-up of patients previously treated by neoadjuvant chemotherapy for triple negative breast cancer.
Timing of blood sampling:
Inclusion
up to 3 other samples, timepoints decided by the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 - &quot;Palbociclib&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Monitoring of patients treated with palbociclib
Timing of blood sampling:
Inclusion day (2 samples)
after #2 weeks of therapy
after #4 weeks of therapy
at progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 - &quot;CTC_PD-L1_Breast&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Detection of PD-L1 in metastatic breast cancer patients
Timing of blood sampling:
Inclusion
up to 3 other samples, timepoints decided by the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8 - &quot;CTC_PD-L1_Broncho-Pulmonary&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Detection of PD-L1 in metastatic lung cancer patients
Timing of blood sampling:
Inclusion
up to 3 other samples, timepoints decided by the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9 - &quot;NSCLC&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.
Blood sampling at 4 timepoints.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 10 - &quot;Palbociclib II&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Monitoring of patient with a metastatic breast cancer treated by palbociclib.
Timing of blood sampling:
Inclusion
after #4 weeks of therapy
at the first tumoral evaluation (month 3 or 4)
at progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 11 - Sarcomas</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The cohort includes all patients with bone or soft tissue sarcoma. Timing of blood sampling depending on disease staging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 12 - Faslorad</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Monitoring of patient with a metastatic breast cancer initiating a treatment by Faslodex-Afinitor.
Timing of blood sampling:
Inclusion
after #3-5 weeks of therapy
at the first tumoral evaluation (month 2 or 3)
at progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 13 - MUm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The cohort concerns patients with uveal melanoma in the 1st systemic line at the metastatic stage (may have had prior adjuvant therapy or surgery/radiofrequency).
Timing of blood sampling:
J1C1
J2C1
J1C2
J1C5 (first tumoral evaluation).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 14 - CNBC Snipe</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This cohort concerns patients with metastatic Non-Small Cell lung Cancer receiving anti-PD-1/PD-L1.
One tumour sampling.
Timing of blood sampling:
before treatment
at W8 of treatment (after radiological examination)
at W12 of treatment
at progression or 18 months after the beginning of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 15 - Breast CLI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This cohort concerns patients with metastatic lobular breast cancer One tumour sampling.
Timing of blood sampling:
At inclusion
After biopsy post inclusion (or in 15 days after)
after 1 or 2 months of treatment
at progression or 18 months after inclusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Up to 5 blood samplings can be performed at different time points</description>
    <arm_group_label>Cohort 1 - &quot;Anti checkpoint&quot;</arm_group_label>
    <arm_group_label>Cohort 10 - &quot;Palbociclib II&quot;</arm_group_label>
    <arm_group_label>Cohort 11 - Sarcomas</arm_group_label>
    <arm_group_label>Cohort 12 - Faslorad</arm_group_label>
    <arm_group_label>Cohort 13 - MUm</arm_group_label>
    <arm_group_label>Cohort 14 - CNBC Snipe</arm_group_label>
    <arm_group_label>Cohort 15 - Breast CLI</arm_group_label>
    <arm_group_label>Cohort 2 - &quot;Oncoscan®&quot;</arm_group_label>
    <arm_group_label>Cohort 3 - &quot;CirCe-PLA&quot;</arm_group_label>
    <arm_group_label>Cohort 4 - &quot;CDX PDX&quot;</arm_group_label>
    <arm_group_label>Cohort 5 - &quot;Post-TP53&quot;</arm_group_label>
    <arm_group_label>Cohort 6 - &quot;Palbociclib&quot;</arm_group_label>
    <arm_group_label>Cohort 7 - &quot;CTC_PD-L1_Breast&quot;</arm_group_label>
    <arm_group_label>Cohort 8 - &quot;CTC_PD-L1_Broncho-Pulmonary&quot;</arm_group_label>
    <arm_group_label>Cohort 9 - &quot;NSCLC&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor sampling</intervention_name>
    <description>One tumor sampling can be performed, if applicable</description>
    <arm_group_label>Cohort 14 - CNBC Snipe</arm_group_label>
    <arm_group_label>Cohort 15 - Breast CLI</arm_group_label>
    <arm_group_label>Cohort 3 - &quot;CirCe-PLA&quot;</arm_group_label>
    <arm_group_label>Cohort 4 - &quot;CDX PDX&quot;</arm_group_label>
    <arm_group_label>Cohort 9 - &quot;NSCLC&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stool sampling</intervention_name>
    <description>Up to 5 blood samplings can be performed at different time points</description>
    <arm_group_label>Cohort 9 - &quot;NSCLC&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with any tumoral disease (proven or suspected), of any type and stage

          2. More than18 years old

          3. Signed informed consent form

             Additional inclusion criteria if a tumor sample is needed:

          4. Tumor considered as accessible by biopsy

          5. Normal blood coagulation tests on the last blood analysis

        Non-inclusion Criteria:

          1. Patient in detention or protected by the law

          2. Patient who cannot comply with the study follow up for geographical, social or
             psychological reasons

             Additional non-inclusion criteria if a tumor sample is needed:

          3. Anticoagulant or antiaggregant that cannot be interrupted for the biopsy

          4. central-nervous system metastases only (unless a diagnostic or curative surgery is
             planned before the inclusion in the study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François-Clément BIDARD, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Curie, Paris (FR)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Sophie PLISSONNIER</last_name>
    <email>anne-sophie.plissonnier@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François-Clément BIDARD, MD PhD</last_name>
    <phone>+33 144 324 682</phone>
    <email>francois-clement.bidard@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>François GHIRINGHELLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William JACOT, MD PhD</last_name>
      <email>William.Jacot@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>William JACOT, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie (Paris hospital)</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François-Clément BIDARD, MD PhD</last_name>
      <email>francois-clement.bidard@curie.fr</email>
    </contact>
    <investigator>
      <last_name>François-Clément BIDARD, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe LOUVET, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe LOUVET, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie (St Cloud hospital)</name>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves PIERGA, MD PhD</last_name>
      <email>jean-yves.pierga@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Yves PIERGA, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>circulating tumor biomarkers</keyword>
  <keyword>circulating tumor DNA</keyword>
  <keyword>Circulating tumor Cell (CTC)</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

